CAMBRIDGE, Mass., July 22, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced the appointment of Mark Sumeray, MD, MS, FRCS, to the executive team as Chief Medical Officer. Dr. Sumeray brings development, regulatory and medical affairs experience with cardiovascular drugs such as Plavix®, apixaban, Avapro®/Avalide®, and Angiomax® to Aegerion.
